Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Pamela Stephenson, Chief Commercial Officer of Disc Medicine, sold 5,531 shares on February 17, 2026, at $62.86 per share for proceeds of $347,678 to satisfy tax withholding tied to vested restricted stock units. The disposition was non-discretionary. Separately, the company is addressing an FDA Complete Response Letter for its EPP candidate bitope…
Disc Medicine's Chief Medical Officer William Jacob Savage sold 3,256 shares on February 17, 2026, to cover tax withholding from vested restricted stock units. The move coincides with a regulatory setback for the company's erythropoietic protoporphyria (EPP) therapy bitopertin, after the FDA issued a Complete Response Letter requesting additional P…
Disc Medicine Chief Operating Officer Jonathan Yen-Wen Yu sold 3,231 shares of the company on February 17, 2026, generating roughly $203,100 to satisfy tax withholding tied to vested restricted stock units. The transaction occurred amid volatility in IRON shares and follows a Complete Response Letter from the U.S. Food and Drug Administration reque…
Coliseum Capital Management and affiliated entities bought Sonos Inc. (SONO) common stock in three separate transactions in February totaling $10,180,585. The acquisitions occurred on February 12, 13 and 17, 2026, at weighted average prices between $15.59 and $16.11. After the buys Coliseum-linked accounts own 16,310,563 Sonos shares. The activity …
On February 13, 2026, Cognex Corp. director Robert Willett sold 2,148 shares of the company and simultaneously exercised options to acquire an identical number of shares. The trades occurred as the stock traded close to its 52-week high and at an elevated valuation on several common metrics. Cognex additionally reported a stronger-than-expected fou…
John L. Hennessy, a director of Alphabet Inc., sold 590 shares of Class A common stock through a trust on February 13, 2026, for roughly $184,036. The disposals took place under a pre-arranged Rule 10b5-1 trading plan and reduced the trust's holding to 20,624 shares. The trades come amid several significant corporate moves for Alphabet, including E…
Disc Medicine Chief Executive John D. Quisel sold 13,264 shares on February 17, 2026, at $62.86 per share, generating proceeds of $833,775 to satisfy tax withholding tied to vesting restricted stock units. The company is simultaneously navigating a regulatory setback for its erythropoietic protoporphyria treatment, bitopertin, after the FDA issued …
An avalanche struck the Castle Peak area near Truckee, California, on Tuesday, burying a party of 16 skiers. Four guides and 12 clients were caught in the slide. Six people survived and remained at the site awaiting rescue; ten were reported missing. Rescue teams from nearby ski operations and dozens of emergency personnel are on scene while hazard…
Asian equities opened higher on Wednesday even as lingering uncertainty about the economic impact of artificial intelligence continued to unsettle investors. Oil prices eased after Iran and the United States reported progress on guiding principles in nuclear negotiations, reducing near-term risk of supply disruption. Currency moves reflected centra…
Pulse Biosciences, Inc. (NASDAQ: PLSE) reported that Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock between February 12 and February 17, 2026, generating $1.41 million. The transactions, executed under a Rule 10b5-1 trading plan adopted May 14, 2025, were carried out at weighted average prices between $23.37 and $…
California’s Department of Motor Vehicles has postponed a planned 30-day suspension of Tesla’s dealer and manufacturer licenses after the automaker ceased using the term "autopilot" in vehicle marketing within the state. The reprieve arrives as Tesla and other electric vehicle makers face a downturn in demand following the end of important sales-bo…
Oil futures nudged down as progress in US-Iran negotiations reduced near-term supply disruption concerns, while reports of recovering output at Kazakhstan's Tengiz field and forthcoming U.S. inventory reports kept traders cautious. Brent and WTI traded near two-week lows, and market attention shifted to weekly API and EIA data that could confirm re…
U.S. stock futures edged lower Tuesday evening after a modest, uneven rebound in technology shares. Market participants are positioning for a series of economic releases and the Federal Reserve's January meeting minutes, which are expected to offer additional clarity on the central bank's interest-rate outlook. Investors monitored heavyweights incl…
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 10,348 shares of common stock on February 12, 2026, in a filing that shows the transaction was executed to satisfy tax withholding tied to vested restricted stock units. The sale, executed at a weighted average price of $9.04 for a total of $93,545, comes as the company reported positive P…
Ocular Therapeutix COO Donald Notman sold 11,446 shares on February 12, 2026, for $103,471 at a weighted average price of $9.04. The sale left him with 366,356 shares. The transaction coincides with the company reporting a Phase 3 superiority result for its investigational wet age-related macular degeneration treatment AXPAXLI, a reaffirmation of a…
Gold prices stabilised in Asian trade following a more than 2% decline the prior session, a fall prompted by improving risk appetite after reported progress in U.S.-Iran negotiations and a stronger U.S. dollar. Market participants awaited the Federal Reserve's January meeting minutes and the U.S. personal consumption expenditures inflation report f…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 7,863 shares on February 12, 2026 to satisfy tax withholding tied to vested restricted stock units, leaving her with 318,417 shares. The transaction coincides with the company’s disclosure of positive Phase 3 SOL-1 results for AXPAXLI in wet age-related macular degeneration, an RBC Cap…
Ocular Therapeutix Executive Chairman, President and CEO Pravin Dugel sold 124,882 shares on February 12, 2026, in a transaction totaling $1.13 million to satisfy tax obligations tied to restricted stock unit vesting. The company also disclosed a successful Phase 3 superiority outcome for its wet age-related macular degeneration candidate AXPAXLI, …
Huntington Ingalls (HII) has lagged some peers in rerating, but recent program wins, robust free cash flow, and a cleaner balance sheet point to a constructive trade. I am upgrading HII to a long trade at $418.25 with a $475 target and a $380 stop, horizon 180 trading days. The risk/reward is attractive given a $16.4B market cap, $794M annual free …
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen (BIIB), purchased three shares of the company's common stock on February 12, 2026, at $195.035 per share for a total of $585. The purchase was recorded on a Form 4 filing and follows strong recent market performance for Biogen, which trades near its 52-week high. Murphy also …
On December 18, 2025, Samsara Opportunity Fund, L.P. bought 479,847 shares of Kalaris Therapeutics at $10.42 per share in a privately negotiated transaction valued at $5,000,005. The trade raises Samsara Opportunity Fund’s direct stake to 1,979,847 shares and follows a disposition from Samsara BioCapital, L.P., which now holds 10,968,234 shares. Ka…
The Reserve Bank of New Zealand held its official cash rate at 2.25%, noting that headline inflation rose to 3.1% in the December 2025 quarter but is expected to fall back within the 1% to 3% target band by the March quarter and drift toward the 2% midpoint over the next year. The central bank said earlier rate cuts have supported a gradual recover…
Micron is trading near $400 after a year of dramatic DRAM/NAND repricing and accelerating revenue. Institutional allocators are rotating in, earnings momentum is visible, and balance-sheet metrics support risk-taking. This trade targets continued DDR5-driven pricing power and share gains into 2026 while protecting capital with a strict stop.
California Attorney General Rob Bonta is creating an AI oversight unit while pressing an investigation into Elon Musk-backed xAI after allegations its Grok chatbot produced sexualized images of real people, including potentially minors. The attorney general's office has sent a cease-and-desist to xAI, is seeking confirmation that the conduct has st…
Equinix Inc.'s Chief Financial Officer, Keith D. Taylor, sold 2,000 shares on February 12, 2026, for $956.44 each, generating roughly $1.9 million. The company has issued 2026 revenue and adjusted funds from operations per share guidance that exceeded Wall Street expectations, reported record bookings and monthly recurring revenue growth, and promp…
